An approach for differentiating echovirus 30 and Japanese encephalitis virus infections in acute meningitis/encephalitis: a retrospective study of 103 cases in Vietnam

Yuki Takamatsu1,2, Leo Uchida1,2, Phan Thi Nga3, Kenta Okamoto1, Takeshi Nabeshima1, Dang Thi Thu Thao3, Do Thien Hai4, Nguyen Thi Tuyet5, Hoang Minh Duc6, Le Xuan Luat1,2, Futoshi Hasebe1 and Kouichi Morita1*

Abstract

Background: In recent decades, Echovirus 30 (E30) and Japanese encephalitis virus (JEV) have been reported to be the common causative agents of acute meningitis among patients in South East Asia. An E30 outbreak in Vietnam in 2001–2002 gained our interest because the initial clinical diagnosis of infected patients was due to JEV infection. There are few clinical insights regarding E30 cases, and there are no reports comparing E30 and JEV acute meningitis/encephalitis cases based on clinical symptoms and case histories. We therefore aimed to identify reliable clinical methods to differentiate E30 and JEV acute meningitis/encephalitis.

Methods: A retrospective, cross-sectional study was conducted to compare E30 and JEV acute meningitis/encephalitis cases. We collected and analyzed the clinical records of 43 E30 confirmed cases (E30 group) and 60 JEV confirmed cases (JEV group). Clinical data were compared between the E30 and the JEV groups. Differences of clinical parameters were analyzed by certain statistical tests.

Results: Fever, headache, and vomiting were the most common symptoms in both the E30 and the JEV groups. Combined symptoms of headache and vomiting and the triad of symptoms of fever, headache, and vomiting were observed in more patients in the E30 group (E30 vs. JEV: 19% vs. 0%, p < 0.001; 74% vs. 27%, p < 0.001, respectively). On the other hand, strong neurological symptoms such as seizure (5% vs. 73%, p < 0.001) and altered consciousness (12% vs. 97%, p < 0.001) were manifested primarily in the JEV group. CSF leukocytosis was observed predominantly in the E30 group (80 vs. 18 cells/μL, p = 0.003), whereas decreasing CSF sugar level was observed predominantly in the JEV group (58.7 vs. 46.9 mg/dL, p < 0.001).

Conclusion: Fever, headache, vomiting, absence of neurological symptoms (seizure, altered consciousness), and presence of CSF leukocytosis are important parameters to consider in differentiating E30 from JEV cases during early infection. Then, proper measures can be adopted immediately to prevent the spread of the disease in the affected areas.

Keywords: Echovirus 30, Japanese encephalitis virus, Acute meningitis/encephalitis

* Correspondence: moritak@nagasaki-u.ac.jp
1Department of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4, Sakamoto, 852-8523 Nagasaki, Japan
Full list of author information is available at the end of the article

© 2013 Takamatsu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

E30 is a positive-strand RNA virus that belongs to the family Picornaviridae, genus Enterovirus [1]. It is transmitted to humans by the oral-fecal route [2]. E30 is responsible for many sporadic outbreaks of aseptic meningitis in many countries because of its easier transmission [1-9].

Japanese encephalitis virus (JEV) is a mosquito-borne virus that belongs to family Flaviviridae, genus Flavivirus [10]. It can cause meningitis or encephalitis in humans. JEV causes approximately 30,000-50,000 meningitis/encephalitis cases annually in Asia, and it is one of the leading causes of the meningitis/encephalitis cases worldwide [10,11]. In recent decades, many E30 outbreaks have occurred in JEV-endemic Asian countries around Vietnam [3,5,12-14]. According to several case reports on meningitis in these countries, an epidemic season of E30 overlapped with that of JEV [5,12,15,16]. Hence, certainty on clinical diagnosis cannot be guaranteed, especially during the early course of illness.

The general symptoms of Enterovirus meningitis are headache, nausea, and vomiting. Common cold symptoms are also observed [1,5]. In some instances, severe illness characterized by paralysis and encephalitis leads to death [9,13]. These symptoms varying from mild to severe manifestations are quite similar to those due to JEV infection [11,17,18]. Thus, a correct identification of the causative agent is difficult to determine based on the clinical symptoms.

Several reports showed that JEV is one of the leading causes of acute meningitis/encephalitis in Vietnam [15,16,18]. However, the number of JEV-confirmed cases was not high enough, and some of the patients were found to actually be infected by enteroviruses instead [18,19]. In this report, we consider only those patients whose admission diagnosis was acute meningitis/encephalitis, and whose infection was confirmed to be due to E30 or JEV by laboratory procedures. Our study focused on the clinical information of these patients, and we found that specific clinical symptoms and laboratory findings could give the clinicians/epidemiologists a more reliable method for differentiating E30 and JEV cases as early as possible.

Materials and methods

Ethical statements

This study was approved by the Institutional Review Board of the National Institute of Hygiene and Epidemiology (NIHE), Vietnam (No: 01 IRB, November 7, 2005, No: 33 IRB, December 15, 2011).

Specimen collection

Cerebrospinal fluid (CSF) specimens were collected only from patients who were clinically diagnosed to have acute meningitis/encephalitis at the time of admission and whose clinical records were available. The patients were from the National Hospital of Pediatrics (NHP) in Hanoi, Northern Vietnam and from Bac Giang General Hospital (BGGH) in Bac Giang, Northern Vietnam. The period of collection at the NHP was from 2001–2002, when an E30 outbreak occurred in Hanoi. The period of collection at BGGH was from 1999 to 2008. NIHE collects clinical specimens from BGGH annually because it is located in a JEV endemic area [16].

Laboratory investigation

CSF specimens were sent to the NIHE for laboratory diagnosis. The E30 cases were identified by the neutralization test (NT) using anti-E30 serum [20]. Several samples that were unidentified by the NT were subjected to the virus isolation and gene amplification method as described below. The JEV cases were confirmed by IgM Capture ELISA [16].

Virus isolation, RT-PCR, and sequencing

Eight unidentified samples were subjected to virus isolation. Each CSF specimen was inoculated in human rhabdomyosarcoma cells (RD cells). The cells were incubated at 37°C with 5% CO₂ until the cytopathic effect (CPE) was observed under a microscope [21,22]. Then, the infected culture fluids (ICFs) were collected and kept at ~80°C prior to use. The viral RNA was isolated from the ICFs by the QIAamp Viral RNA Mini Kit (QIAGEN) according to the manufacturer’s instructions [23]. To amplify the complete VP1 gene of E30, RNA templates were subjected to reverse transcription and polymerase chain reaction (RT-PCR) using the forward primer 5’-GCRTCAGATGAYTTCTCGWGT-3’ and the reverse primer 5’-GCCICGYGTIGGCRAA-3’ [24]. The amplicons were sequenced using the ABI PRISM 3100-Avant Genetic Analyzer [25].

Phylogenetic analysis

Phylogenetic analysis of selected strains of human E30 from different geographical origins was performed based on the VP1 gene sequences (Figure 1). Alignment of these sequences was performed by Clustal W version 2.0 [26], and a neighbor-joining tree [27] was generated using MEGA 5.0 software [28]. The prototype strain Farina of Echovirus 21 (GenBank accession number: AY302547) was used as the out-group. The reliability of the phylogenetic tree was determined by a bootstrap resampling test with 1,000 replicates.

Clinical data and statistical analysis

The clinical data from E30-confirmed cases (E30 group) and JEV-confirmed cases (JEV group) were included in the statistical analysis. The statistical analysis was conducted using R version 2.15 software [29]. The difference between
Figure 1 (See legend on next page.)
the E30 and the JEV groups was tested by Chi-squared tests and Fisher Exact tests. The distribution of values between these groups was compared by the F test, and the difference of values between them was assessed by Student’s t-tests or Welch tests. A P value of less than 0.05 was accepted as significant.

Results

Laboratory confirmation of E30 and JEV infection

Eighty-eight patients from NHP were confirmed to have E30 infection based on NT (80 patients) and virus isolation (8 patients) (Figure 2). One hundred thirty-four patients at BGGH were confirmed to have JEV infection by IgM Capture ELISA (Figure 2).

Virus isolation, sequence comparison, and phylogenetic analysis

E30 was isolated from eight CSF specimens. The VP1 gene in these isolates was sequenced. The designated strain name of each isolate and the corresponding GenBank accession number (enclosed in parentheses below) were as follows: 01VN80 (KC999616), 01VN89 (KC999617), 01VN90 (KC999618), 01VN92 (KC999619), 01VN102 (KC999620), 01VN104 (KC999621), 02VN24 (KC999622), and 02VN28 (KC999623).

We constructed the NJ tree of these eight Vietnamese strains together with the 88 E30 strains from GenBank based on the VP1 gene sequence. Based on this tree, our identified strains were relatively close to the Asian strains that caused aseptic meningitis (Figure 1).

Epidemiological features

Most patients were under 15 years old in both the E30 and the JEV groups. The median age was 7 in the former group and 6 in the latter group. In the E30 group, there were 30 male patients (70%) and 13 female patients (30%), with a male-to-female ratio of 2.3:1. In the JEV group, there were 22 male patients (37%) and 38 female patients (63%), with a male-to-female ratio of 1:1.7. The percentage of JEV-vaccinated patients in the E30 group was significantly higher than that in the JEV group (E30 vs. JEV: 56% vs. 12%, p < 0.001) (Table 1). Fatal (12%) and sequelae (10%) cases were observed in the JEV group only (Table 1). Both E30 and JEV cases occurred more frequently during the summer season from May to July (Figure 3).

Clinical features during admission

The clinical features during admission of the E30 and the JEV patients are shown in Table 2. The vital sign parameters (body temperature, pulse rate, and respiratory rate) on admission day showed no significant difference between the two groups of patients. A longer hospitalization period was observed in the JEV group than in the E30 group (E30 vs. JEV: 7 [range: 3–23] vs. 9 [1–37] days, p = 0.003). More patients in the E30 group complained of headache (95% vs. 50%, p < 0.001), vomiting (98% vs. 33%, p < 0.001), abdominal symptoms (19% vs. 5%, p = 0.048), and neck or back pain (26% vs. 2%, p < 0.001). On the other hand, more patients in the JEV group had a higher maximum body temperature (38.0 [37.0-41.0] °C, p = 0.010), altered consciousness (12% vs. 97%, p < 0.001), and seizures (5% vs. 73%, p < 0.001). The periods of altered consciousness (1 [1-3] vs. 3 [1-17] days, p = 0.002), seizures (1 [1] vs. 2 [1-7] days, p < 0.001), Babinski reflex (1 [1-3] vs. 2 [1-7] days, p = 0.001), and focal neurological signs (1 [1] vs. 2.5 [1-13] days, p = 0.037) lasted longer in the JEV group. Both groups had a similar percentage of patients with signs of meningeal irritations, whereas the duration period was longer in the JEV
group (1 [1-6] vs. 3 [1-14] days, p = 0.002). More patients in the JEV group experienced Babinski reflex (42% vs. 62%, p = 0.047), and with a longer duration (1 [1-3] vs. 2 [1-7] days, p = 0.001). Hemiplegia was observed only in the JEV group (25%, p < 0.001).

We also focused on the symptoms observed simultaneously. The combined symptoms of headache and vomiting and the triad of symptoms of fever, headache, and vomiting were observed in more patients in the E30 group (19% vs. 0%, p < 0.001 and 74% vs. 27%, p < 0.001, respectively). On the other hand, occurrence of the combined symptoms of fever and headache was observed only in the JEV group (18%, p = 0.002).

Laboratory findings

The results of the CSF and blood examination are shown in Table 3. CSF leucocytes were significantly increased in the E30 group (80 [1–750] vs. 18 [5–350] cells/μL, p = 0.003). An increased number of both CSF neutrophils and CSF lymphocytes was observed in the E30 group (neutrophils: 26 [2–381] vs. 10 [3–140] cells/μL, p = 0.033, lymphocytes: 56 [3–676] vs. 12 [4–210] cells/μL, p = 0.043). The CSF sugar levels were significantly decreased in the JEV group (58.7 [27–90] vs. 46.9 [25–74] mg/dL, p < 0.001). Other indicators of CSF and blood components showed no significant difference between the E30 and the JEV groups.

Treatment features

The laboratory diagnosis required at least one week to complete, thus medication was given even before the results of the diagnosis became available. The medication histories of the E30 and the JEV groups are shown in Table 4. A history of the use of steroids showed no significant difference between the two groups (E30 vs. JEV: 98% vs. 97%). The duration of steroids use also showed no difference in both groups (3 [2-4] vs. 3 [2-15] days). More patients were prescribed mannitol (47% vs. 95%, p < 0.001) and antibiotics (35% vs. 95%, p < 0.001) in the JEV group. The duration of mannitol use was longer in the JEV group (1 [1-3] vs. 3 [1-7] days, p < 0.001). A history of the use of diazepam showed no significant difference between the two groups. The duration of diazepam use was longer in the E30 group (6 [2-14] vs. 2 [1-11] days, p < 0.001). More patients in the JEV group were prescribed barbiturates (33% vs. 63%, p = 0.002), chlorpromazine (5% vs. 23%, p = 0.012), fentanyl (0% vs. 33%, p < 0.001), and sodium valproate (0% vs. 33%, p < 0.001).

Discussion

E30 and JEV are the causative agents of acute meningitis/encephalitis in Asian countries. In the present report, Vietnamese patients with an admitting diagnosis of acute meningitis/encephalitis were confirmed to have either E30 or JEV infection by a laboratory diagnosis. The E30 CSF samples analyzed in the present study were collected during the outbreak in 2001–2002. Eight E30 strains were isolated from this outbreak, and the phylogenetic analysis showed that these are relatively close to the strains isolated during E30 outbreaks from other Asian countries (Figure 1).

The E30 acute meningitis/encephalitis outbreak in 2001–2002 gained our interest because nearly all of the patients were clinically diagnosed to have Japanese encephalitis at the beginning of their hospitalization. The reason

| Table 1 Basic patient information and outcome | E30 patients | JEV patients | p-value |
|---------------------------------------------|-------------|-------------|--------|
| Median age [range] or number of patients (%)|             |             |        |
| Age                                         | 7 [0.4-14]  | 6 [0.8-21]  | 0.916  |
| Sex                                         | Male 30 (70)| Female 13 (30)|        |
| Family/neighbor history                      | 1 (2)       | 1 (2)       | 0.628  |
| JEV vaccination                              | 24 (56)     | 7 (12)      | <0.001*|
| Death                                       | 0 (0)       | 7 (12)      | 0.040* |
| Sequelea                                    | 0 (0)       | 6 (10)      | 0.039* |

*significant difference (p < 0.05).
for this initial diagnosis could be the lack of clear guidelines for differentiating E30 from JEV infections based on the clinical symptoms and case histories. Our study is the first report to show that certain clinical features could differentiate E30 from JEV cases.

We tried to compare the symptoms and clinical features between the two groups before admission, according to the information in the clinical record (unpublished data). However, there was no sufficient difference noted between the E30 and the JEV cases compared to those during admission (Table 2). Then, we focused our attention on the data during the admission period. Here, we noted that the most common symptoms were fever, headache, and vomiting for both the E30 and the JEV groups (Table 2). More patients in the E30 group had the combined symptoms of headache and vomiting and the triad of symptoms (fever, headache, and vomiting) (Table 2). Thus, it is concluded that these combined symptoms could indicate a high probability of E30 infection. Findings on magnetic resonance imaging (MRI) of patients in the E30 cases revealed no significant abnormalities in the brain [7]. It seems that the mild neurological symptoms observed in

| Clinical feature(s)                                      | Median [range] or, number of patients with the feature (%) | p-value |
|----------------------------------------------------------|------------------------------------------------------------|---------|
| Body temperature (°C)                                    | E30 patients n = 43                                        | JEV patients n = 60                                   |
|                                                          | 38.0 [36.2-41.0]                                            | 38.5 [36.5-40.0]                                        | 0.096   |
| Pulse rate (beats per min.)                              | 100 [80-120] [34]                                          | 100 [70-145] [58]                                       | 0.092   |
| Respiratory rate (breaths per min.)                      | 26 [20-45] [13]                                            | 26 [20-50] [31]                                         | 0.691   |
| Length of stay in the hospital (day)                     | 7 [3-23]                                                   | 9 [1-37]                                                | 0.003*  |
| Highest body temperature (°C)                            | 38.0 [37.0-41.0]                                            | 38.8 [37.0-40.0]                                        | 0.010*  |
| Period of fever (day)                                    | 1 [1-14]                                                   | 2 [1-7]                                                 | 0.259   |
| Headache                                                | 41 (95)                                                    | 30 (50)                                                 | < 0.001*|
| Period of headache (day)                                 | 2 [1-7] [41]                                               | 2.5 [1-12] [30]                                         | 0.006*  |
| Vomiting                                                | 42 (98)                                                    | 20 (33)                                                  | < 0.001*|
| Period of vomiting (day)                                 | 1 [1-5] [42]                                               | 1 [1,2] [20]                                            | 0.526   |
| Altered consciousness                                    | 5 (12)                                                     | 58 (97)                                                  | < 0.001*|
| Period of altered consciousness (day)                    | 1 [1-3] [5]                                                | 3 [1-17] [58]                                           | 0.002*  |
| Seizure                                                  | 2 (5)                                                      | 44 (73)                                                  | < 0.001*|
| Period of seizure (day)                                  | 1 [1] [2]                                                  | 2 [1-7] [44]                                            | < 0.001*|
| Sign of meningeal irritation                             | 30 (70)                                                    | 41 (68)                                                  | 0.877   |
| Period of meningeal irritation (day)                     | 1 [1-6] [30]                                               | 3 [1-14] [41]                                           | 0.002*  |
| Babinski reflex                                          | 18 (42)                                                    | 37 (62)                                                  | 0.047*  |
| Period of Babinski reflex (day)                          | 1 [1-3] [18]                                               | 2 [1-7] [37]                                            | 0.001*  |
| Focal neurological sign                                  | 2 (5)                                                      | 10 (17)                                                  | 0.070   |
| Period of focal neurological sign (day)                  | 1 [1] [2]                                                  | 2.5 [1-13] [10]                                         | 0.037*  |
| Dyspnea                                                 | 2 (5)                                                      | 10 (17)                                                  | 0.070   |
| Hemiplegia                                              | 0 (0)                                                      | 15 (25)                                                  | < 0.001*|
| Fatigue                                                  | 14 (33)                                                    | 22 (37)                                                  | 0.666   |
| Abdominal symptom                                        | 8 (19)                                                     | 3 (5)                                                     | 0.048*  |
| Neck or back pain                                        | 11 (26)                                                    | 1 (2)                                                     | < 0.001*|
| Joint pain                                               | 1 (2)                                                      | 0 (0)                                                     | 0.235   |
| Skin rash                                                | 0 (0)                                                      | 1 (2)                                                     | 0.395   |
| Fever + Headache                                         | 0 (0)                                                      | 11 (18)                                                   | 0.002*  |
| Headache + Vomiting                                      | 8 (19)                                                     | 0 (0)                                                     | < 0.001*|
| Vomiting + Fever                                         | 4 (9)                                                      | 2 (3)                                                     | 0.232   |
| Fever + Headache + Vomiting                              | 32 (74)                                                    | 16 (27)                                                   | < 0.001*|

1taken on the day of admission, 2number inside curly brackets refer to the number of patients with the record, 3fever defined as body temperature of over 38°C, *significant difference (p < 0.05).
the E30 group are not from direct neuronal damage, but from increased intracranial pressure. Therefore, vomiting, which is one of the important signs of increased intracranial pressure, was often observed in the E30 group compared to the JEV group in this study.

More patients had altered consciousness (97%), seizure (73%), and hemiplegia (25%) in the JEV group (Table 2). These symptoms are strong signs of neural pathogenicity. It was reported that the JEV patients showed abnormalities in thalamus, basal ganglia, and cerebral cortex based on the results of computed tomography (CT) and MRI [30-32]. However, it is difficult to conduct these expensive examinations in a resource limiting setting in the rural areas of Asian countries. Neuropathological findings in fatal JEV cases showed that the virus caused broad inflammation in the central nervous system [33]. JEV infects neurons and causes direct damage [10,33] that consequently leads to many severe neurological symptoms. Thus, in areas where E30 and JEV outbreaks are overlapping, severe neurological symptoms could provide strong evidence of JEV infection.

The most critical laboratory finding in this report was the CSF leukocytosis in the E30 group (Table 3). An increase in CSF neutrophils was observed, and this was also reported in another study [34]. An increase in CSF lymphocytes was observed in the present study. Therefore, these results seem to suggest that CSF leukocytosis relates to the E30 infection.

Based on the medication history, more patients were prescribed barbiturates, chlorpromazine, fentanyl, and sodium valproate in the JEV group (Table 4). This seems to correlate with the longer period of neurological symptoms such as altered consciousness and seizures in the JEV

---

**Table 3 CSF and blood examination**

|                      | Median value (range), [number of patients] |
|----------------------|--------------------------------------------|
|                      | E30 patients | JEV patients | p-value |
|                      | n = 43       | n = 60       |        |
| CSF protein (mg/dL)  | 36.3 (14–144) [39] | 44.5 (6–100) [47] | 0.093 |
| CSF sugar (mg/dL)    | 58.7 (27–90) [38] | 46.9 (25–74) [47] | < 0.001* |
| CSF leucocyte (cells/μL) | 80 (1–750) [41] | 18 (5–350) [45] | 0.003* |
| CSF neutrophil (cells/μL) | 26 (2–381) [23] | 10 (3–140) [35] | 0.033* |
| CSF lymphocyte (cells/μL) | 56 (3–676) [23] | 12 (4–210) [35] | 0.043* |
| Blood leucocyte (10E3 cells/μL) | 10.4 (5.8-34) [19] | 12.0 (3.0-30) [59] | 0.711 |
| Blood neutrophil (10E3 cells/μL) | 8.2 (3.9-25) [18] | 8.0 (1.1-26) [57] | 0.368 |
| Blood lymphocyte (10E3 cells/μL) | 2.1 (1.3-9.6) [18] | 3.2 (1.3-12) [57] | 0.189 |

*significant difference (p < 0.05).

**Table 4 Treatment features**

|                      | Number of patients (%), median day [range] | p-value |
|----------------------|--------------------------------------------|---------|
|                      | E30 patients | JEV patients |       |
|                      | n = 43       | n = 60+      |       |
| Steroids             | 42 (98)      | 58 (97)      | 0.769 |
| Period of treatment  | 3 [2-4]      | 3 [2-15]     | 0.204 |
| Mannitol             | 20 (47)      | 57 (95)      | < 0.001* |
| Period of treatment  | 1 [1-3]      | 3 [1-7]      | < 0.001* |
| Antibiotics          | 15 (35)      | 57 (95)      | < 0.001* |
| Period of treatment  | 8 [1-15]     | 8 [1-17]     | 0.688 |
| Diazepam             | 23 (53)      | 32 (53)      | 0.988 |
| Period of treatment  | 6 [2-14]     | 2 [1-11]     | < 0.001* |
| Barbiturate          | 14 (33)      | 38 (63)      | 0.002* |
| Period of treatment  | 3.5 [1-14]   | 2.5 [1-11]   | 0.130 |
| Chlorpromazine       | 2 (5)        | 14 (23)      | 0.012* |
| Fentanyl             | 0 (0)        | 20 (33)      | < 0.001* |
| Sodium Valproate     | 0 (0)        | 20 (33)      | < 0.001* |

*significant difference (p < 0.05).
group. We would like to indicate that medication strategies have been established in each hospital, however some minor differences in these strategies exist between hospitals.

Patients in the E30 group had a higher male-to-female ratio of 2.3:1. A higher ratio was also shown in previous reports [34,35]. Boys usually prefer to play outside of their house compared with girls. This behavior could result in a more frequent exposure of boys to the pathogen.

Conclusion
Clinical information demonstrated that the combination of headache and vomiting and the triad of symptoms of fever, headache, and vomiting could indicate a high probability of E30 infection. A laboratory parameter of CSF leukocytosis also suggests E30 infection. On the other hand, strong neurological symptoms, such as altered consciousness, seizure, and hemiplegia, could indicate a high probability of JEV infection. These findings will help improve the clinical diagnosis of patients with E30 or JEV meningitis/encephalitis. Then, proper measures can be adopted for the clinical management of the patients at the early phase of admission before laboratory diagnosis becomes available.

Abbreviations
E30: Echovirus 30; JEV: Japanese encephalitis virus; CSF: Cerebrospinal fluid; NHE: National Institute of Hygiene and Epidemiology; NT: Neutralization test; RD cells: Rhabdomyosarcoma cells; ICF: Infected Culture Fluid; CPE: Cytopathic effect; RT-PCR: Reverse transcription and polymerase chain reaction.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
DTH, NIT, HMD, and PTN contributed to the collection of the specimens and clinical diagnosis. NTF and FH contributed to the laboratory diagnosis. YT, LU, KO, and TN performed the genome analysis and cell culture. YT, DTH, NIT, HMD, and PTN contributed to the collection of the specimens and clinical diagnosis. These authors read and approved the final version of the manuscript.

Acknowledgements
This study was supported by the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan through the following programs: Grant-in-Aid for Scientific Research, Grant-in-Aid for JSPS Fellows (Japan Society for the Promotion of Science), Global COE Program, Japan Initiative for Global Network on Infectious Diseases (J-GRID), and Young Researcher Overseas Visits Program for Vitalizing Brain Circulation, and by the Ministry of Health, Labour, and Welfare, Japan through the Grant-in-aid for scientific research. The authors acknowledge Dr. Nguyen Thi Hien Thanh from the Department of Virology, National Institute of Hygiene and Epidemiology, Vietnam, for providing the information on E30 laboratory diagnosis; Dr. Corazon C. Buenaro from the Department of Molecular Epidemiology, Institute of Tropical Medicine, Nagasaki University, for editing and proofreading the manuscript.

Author details
1Department of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4, Sakamoto, 852-8523 Nagasaki, Japan. 2Graduate school of Biochemical Sciences, Nagasaki University, Nagasaki, Japan. 3Department of Training and Research Management, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam. 4Department of Infectious Disease, National Hospital of Pediatrics, Hanoi, Vietnam. 5Department of Infectious Disease, Bac Giang General Hospital, Bac Giang, Vietnam. 6Department of Preventive Medicine, Ministry of Health, Hanoi, Vietnam.

Received: 13 May 2013 Accepted: 9 September 2013

References
1. Hyypia T, Hovi T, Knowles NJ, Stanway G. Classification of enteroviruses based on molecular and biological properties. J Gen Virol 1997, 78(Pt 1):1–11.
2. Brunel D, Leveque N, Jacques J, Renois F, Motte J, Andreoletti L. Clinical and virological features of an aseptic meningitis outbreak in north-eastern France, 2005. J Clin Virol 2008, 42:225–228.
3. Baek K, Yoo S, Lee B, Park K, Song J, Yu J, Rheem J, Kim J, Hwang S, Choi Y, et al. Epidemiology of enterovirus infection in Chungnam Korea, 2008 and 2009. Virol J 2011, 8:297.
4. Mitekuncho AS, Viegas M, Latta MP, Barrero PR. Molecular and epidemiologic analysis of enterovirus B neurological infection in Argentine children. J Clin Virol 2006, 32:293–299.
5. Kim HJ, Kang B, Hwang S, Hong J, Kim K, Cheon DS. Epidemics of viral meningitis caused by echovirus 6 and 30 in Korea in 2008. Virol J 2012, 9:38.
6. Kumar A, Shukla D, Kumar R, Idris MZ, Misra UK, Dhole TN. An epidemic of encephalitis associated with human enterovirus 81 in Uttar Pradesh, India, 2008. J Clin Virol 2011, 51:142–145.
7. Nishikawa M, Matsutara T, Yoshitomi T, Ichiyama T, Hayashi T, Furukawa S. Abnormalities of brain perfusion in echovirus type 30 meningitis. J Neurol Sci 2000, 179:122–126.
8. Diedrich S, Schreier E. Aseptic meningitis in Germany associated with echovirus type 13. BMC Infect Dis 2001, 1:14.
9. Tseng FC, Huang HC, Chi CY, Lin TI, Liu CC, Jian JW, Hsu LC, Wu HS, Yang YJ, Chang YW, et al. Epidemiological survey of enterovirus infections occurring in Taiwan between 2000 and 2005: analysis of sentinel physician surveillance data. J Med Virol 2007, 79:1859–1866.
10. Sips GJ, Wilschut J, Smit JM. Neuroinvasive flavivirus infections. Rev Med Virol 2012, 22:69–87.
11. Solomon T. Flavivirus encephalitis. N Engl J Med 2004, 351:370–378.
12. Wang JR, Tsai HP, Huang SW, Kuo PH, Kiang D, Liu CC. Laboratory diagnosis and genetic analysis of an echovirus 30-associated outbreak of aseptic meningitis in Taiwan in 2001. J Clin Microbiol 2002, 40:4439–4444.
13. Han JF, Cao RY, Jiang T, Yu M, Liu W, Tian X, Qin ED, Cao WC, Qin CF. Echovirus 30 in EV71-associated hand, foot and mouth disease outbreak, Guangxi, China. J Clin Virol 2011, 50:348–349.
14. Hsu CH, Lu CY, Shao PL, Lee PI, Kao CL, Chung MY, Chang LY, Yang YJ, Chang YW, et al. Epidemiologic survey of enterovirus infections in eastern France, 2005.
15. Lowey PW, Truong DT, Hinh LD, Laidinsky J, Karabatis N, Cropp CB, Martin D, Gubier DJ. Japanese encephalitis among hospitalized pediatric and adult patients with acute encephalitis syndrome in Hanoi, Vietnam 1995. Am J Trop Med Hyg 1998, 59:242–249.
16. Yen NT, Duffy MR, Hong NM, Hien NT, Fischer M, Hills SL. Surveillance for Japanese encephalitis in Vietnam, 1998–2007. Am J Trop Med Hyg 2010, 83:816–819.
17. Rayamajhi A, Ansari I, Ledger E, Bista KP, Impoinvil DE, Nightingale S, Kumar R, Mahaseet C, Solomon T, Griffiths MJ. Clinical and prognostic features among children with acute encephalitis syndrome in Nepal: a retrospective study. BMC Infect Dis 2011, 11:294.
18. Borah J, Dutta P, Khan SA, Mahanta J. A comparison of clinical features of Japanese encephalitis virus infection in the adult and pediatric age group with acute encephalitis syndrome. J Clin Virol 2011, 52:45–49.
19. Le VT, Phan TQ, Do QH, Nguyen BH, Lam QB, Bach VC, Truong HK, Tran TH, Nguyen W, Tran TT, et al. Viral etiology of encephalitis in children in southern Vietnam: results of a one-year prospective descriptive study. PloS Negl Trop Dis 2010, 4:e854.
20. Melnick JL, Hampil B. WHO collaborative studies on enterovirus reference antisera; fourth report. Bull World Health Organ 1973, 48:381–396.
21. Bell EJ, Cosgrove BP. Routine enterovirus diagnosis in a human rhabdomyosarcoma cell line. Bull World Health Organ 1980, 58:423–428.
22. Parquet MC, Kumatari A, Hasebe F, Mathenge EG, Morita K, St Louis encephalitis virus induced pathology in cultured cells. Arch Virol 2002, 147:105–119.
23. Espada-Murao LA, Morita K: Delayed cytosolic exposure of Japanese encephalitis virus double-stranded RNA impedes interferon activation and enhances viral dissemination in porcine cells. J Virol 2011, 85:6736–6749.

24. Oberste MS, Maher K, Kennett ML, Campbell JJ, Carpenter MS, Schnurr D, Pallansch MA: Molecular epidemiology and genetic diversity of echovirus type 30 (EV30): genotypes correlate with temporal dynamics of EV30 isolation. J Clin Microbiol 1999, 37:3928–3933.

25. Hayasaka D, Gitsun TS, Yoshii K, Ueki T, Goto A, Mizutani T, Katwa H, Iwasaki T, Gould EA, Takashima I: Amino acid changes responsible for attenuation of virus neurovirulence in an infectious cDNA clone of the oshima strain of tick-borne encephalitis virus. J Gen Virol 2004, 85:1007–1018.

26. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, et al: Clustal W and clustal X version 2.0. Bioinformatics 2007, 23:2947–2948.

27. Tamura K, Nei M: Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol 1993, 10:512–526.

28. Takamatsu et al: An approach for differentiating echovirus 30 and Japanese encephalitis virus infections in acute meningitis/encephalitis: a retrospective study of 103 cases in Vietnam. Virology Journal 2013 10:280.